Savolitinib for Brain Tumors

"This research study is primarily based at Lucile Packard Children's Hospital Stanford University in Palo Alto, California, Children's Hospital Colorado in Aurora, Colorado and Nationwide Children's Hospital in Columbus, Ohio; however there are also other 10 sites participating."

"This medicinal trial, which will be monitored for up to a month post-treatment, seeks to ascertain the appropriate phase II dosage. Secondary objectives encompass population parameters (which can be estimated using nonlinear mixed effects modeling methods), objective responses by dose and histology, as well as pharmacokinetic assessments such as volume of central compartment, elimination rate constant, half-life, apparent oral clearance and area under plasma concentration time curve (all of these can be deduced via compartmental methods). Additionally one-way ANOVA analysis on normalized doses shall determine proportionality in kinetic parameters."

"At present, there are 17 underway trials for Savolitinib with 5 of them in the third phase. Though numerous research centers for this medication exist in Westerville, Ohio, it is available at 1156 other medical facilities as well."

"Those that wish to be part of this clinical trial must fall between the ages 6 and 21. There are 556 medical trials currently recruiting for minors, while 3264 studies focus on individuals aged 65 or older."

"The safety of Savolitinib has not been fully evaluated, thus receiving a score of 1. This is because this trial is only in Phase 1 - meaning that there are limited studies to support its efficacy and security."

"Affirmative. The clinicaltrials.gov webpage attests that this medical experiment is currently enrolling participants, having been first posted on October 15th 2018 and last revised on the 19th of October 2022. 50 people are being sought from 10 different sites for involvement in the trial."

"Currently, 17 trials are underway for the drug Savolitinib across 415 cities and 34 countries. The first trial of its kind was initiated by AstraZeneca in 2014 which concluded Phase 2 approval with 999 participants. In the intervening years, 16 more have been conducted accordingly."

"Affirmative. According to clinicaltrials.gov, this medical research is currently enrolling participants from 10 different sites and requires 50 individuals in total to participate. The trial was initially launched on October 15th, 2018 and has been updated as recently as the 19th of October 2022."

"Eligibility criteria for this medical trial necessitates that patients have a diagnosis of medulloblastoma and be between the ages 6 to 21. The study plans on recruiting up to 50 people."